Literature DB >> 21496808

Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.

Amy Baigent1, Hany Lashen.   

Abstract

OBJECTIVE: To report the management of a rare case of ovarian hyperstimulation syndrome (OHSS) induced by tamoxifen therapy for breast cancer in a 50-year-old woman.
DESIGN: Case report.
SETTING: Gynecology outpatient department of a university hospital. PATIENT(S): A 50-year-old premenopausal patient with a history of breast cancer was prescribed adjuvant treatment with tamoxifen. INTERVENTION(S): Temporary discontinuation of tamoxifen therapy resolved symptoms, but resumption of tamoxifen caused a recurrence of symptoms. Surgical bilateral salpingo-oophrectomy was therefore performed. MAIN OUTCOME MEASURE(S): Resolution of symptoms of OHSS. RESULT(S): Bilateral salpingo-oophrectomy rendered the patient postmenopausal and enabled the commencement of the aromatase inhibitor anastrozole as an alternative adjuvant therapy for breast cancer. CONCLUSION(S): Tamoxifen-induced OHSS is rare. Furthermore, OHSS is very rare in the older female. OHSS usually resolves with temporary discontinuation of tamoxifen, however, the recurrence of symptoms when resuming tamoxifen is better treated with bilateral salpingo-oophorectomy to enable adjuvant treatment with anastrazole.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21496808     DOI: 10.1016/j.fertnstert.2011.03.070

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

1.  Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer.

Authors:  Nobue Kojima; Yui Yamasaki; Houu Koh; Masaru Miyashita; Hiroki Morita
Journal:  Case Rep Obstet Gynecol       Date:  2018-01-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.